Approximately 50% of patients with chronic hepatitis C fail to achieve a sustained virological response to standard therapy with pegylated interferon and ribavirin. Progression to advanced liver disease (which may lead to hepatic decompensation, hepatocellular carcinoma, and death) is common in these patients, but can low-dose pegylated interferon maintenance therapy improve outcomes?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Di Bisceglie, A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359, 2429–2441 (2008).
Poynard, T. et al. Impact of pegylated interferon α-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303–1313 (2002).
Veldt, B. J. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147, 677–684 (2007).
Mallet, V. et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 149, 399–403 (2008).
Afdhal, N. H. et al. Colchicine versus PEG-interferon alfa 2b long term therapy: Results of the 4 year copilot trial. J. Hepatol. 48, S4 (2008).
Poynard, T. et al. Sustained virologic response (SVR) in the EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving peg-intron/rebetol (PR) weight based dosing (WBD). J. Hepatol. 42, 40–41 (2005).
Papatheodoridis, G. V., Papadimitropoulos, V. C. & Hadziyannis, S. J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther. 15, 689–698 (2001).
Camma, C., Giunta, M., Andreone, P. & Craxi, A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol. 34, 593–602 (2001).
Seeff, L. B. et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47, 605–612 (2008).
Zeuzem, S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 610–622 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W. P. Hoffman is on the Speaker's bureau for Novartis and Roche. S. Zeuzem is a Consultant and is on the Speaker's bureau for Human Genome Sciences, Novartis, Roche, Schering Plough.
Rights and permissions
About this article
Cite this article
Hofmann, W., Zeuzem, S. New therapeutic strategies needed for advanced disease. Nat Rev Gastroenterol Hepatol 6, 325–327 (2009). https://doi.org/10.1038/nrgastro.2009.63
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.63
This article is cited by
-
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation
Medical Microbiology and Immunology (2010)